SR9009 is a compound that can lead to a wide range of health benefits in animals, including reduced risk of obesity and type 2 diabetes. Until now, researchers—and companies that sell the compound for human use in the form of a nutraceutical—have attributed the effects to SR9009's role in altering the body's circadian clock, specifically its work through proteins called REV-ERBS that link metabolism and circadian rhythm. However, in a first-of-its-kind study from Penn Medicine, published today in PNAS, researchers found that SR9009 can effect cell growth and metabolic function without the involvement of REV-ERBs.
* This article was originally published here
